Biotech | April 25, 2022
‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
April 25th is commemorated as World Malaria Day
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
Subscribe To Our Newsletter & Stay Updated
